Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Nerima-ku, Japan Clinical Trials

A listing of Nerima-ku, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (22) clinical trials

An Investigational Immuno-therapy Study to Evaluate the Safety and Effectiveness of Experimental Medication BMS-986207 by Itself and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread

The purpose of this study is to evaluate the safety and effectiveness of experimental medication BMS-986207 by itself and in combination with Nivolumab in solid cancers that are advanced or have spread.

Phase

8.35 miles

Learn More »

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability, and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer. HER3 is a unique member of the human epidermal growth factor receptor, which defines a certain type of cancer. The number of patients and treatment cycles are not ...

Phase

8.35 miles

Learn More »

Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

Phase 1b To evaluate the safety and tolerability of multiple ascending doses of AMG 592 in subjects with steroid refractory cGVHD. Phase 2 To evaluate the efficacy of AMG 592 in subjects with steroid refractory cGVHD as measured by ORR at 16 weeks according to the 2014 cGVHD NIH Consensus ...

Phase

8.35 miles

Learn More »

An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

The purpose of this study is to determine whether BMS-986258 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced malignant tumors

Phase

8.35 miles

Learn More »

An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab and Nivolumab Combination Therapy in Virus-associated Tumors

The purpose of this study to investigate the safety and effectiveness of nivolumab, and nivolumab combination therapy, to treat patients who have virus-associated tumors. Certain viruses have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drugs, in patients ...

Phase

8.35 miles

Learn More »

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.

Phase

8.35 miles

Learn More »

Study of DS-7300a in Participants With Advanced Solid Malignant Tumors

This study is in one single group of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. The primary purpose of the parts are: Dose Escalation Part: To ...

Phase

8.35 miles

Learn More »

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

The reason for this study is to see if the study drug LY3499446 is safe and effective in participants with solid tumors with KRAS G12C mutation.

Phase

8.35 miles

Learn More »

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia

Enroll patients after confirming eligibility. Following enrollment, peripheral blood mononuclear cells and blood plasma will be obtained from each subject by apheresis to start the manufacturing of TBI-1501. Before TBI-1501 administration, it is necessary to pass the quality tests. Subject will be hospitalized from Day -3 to Day 28, and ...

Phase

8.4 miles

Learn More »

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

This study is composed of Phase 1 part (the dose-evaluation part and the expansion part) and Phase 2 part. In the dose-evaluation part of Phase 1 part, at least 3 subjects will receive ASP2215 at each dose (low, middle, and high) for determination of MTD and/or RED. Treatment of AML ...

Phase

9.79 miles

Learn More »